Castle Biosciences (CSTL) Non-Current Assets (2018 - 2026)

Castle Biosciences has disclosed Non-Current Assets across 9 years of filings, most recently posting $218.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $218.9 million, up 43.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $837.6 million (up 26.89% YoY), and the FY2025 annual result was $217.5 million, up 27.11% from the prior year.
• Non-Current Assets came in at $218.9 million for Q1 2026 at Castle Biosciences, up from $217.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $218.9 million in Q1 2026 to a low of $108.0 million in Q1 2022.
• The 5-year median for Non-Current Assets is $158.4 million (2022), against an average of $168.3 million.
• Across the five-year window, Non-Current Assets jumped 912.79% in 2022 and declined 6.39% in 2025, its largest moves.
• Castle Biosciences' Non-Current Assets stood at $155.0 million in 2022, then climbed by 1.72% to $157.7 million in 2023, then gained by 8.48% to $171.1 million in 2024, then gained by 27.11% to $217.5 million in 2025, then rose by 0.66% to $218.9 million in 2026.
• The last three Non-Current Assets figures came in at $218.9 million (Q1 2026), $217.5 million (Q4 2025), and $205.2 million (Q3 2025), per Business Quant data.